Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
-
April
-
May
-
June
-
July
-
August
-
September
-
Oktober
- November -
December
|
2002
-
2003
-
2004
- 2005 -
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
-
2024
-
2025
November 2005 - 37 products
L
IP
CI
Inegy 10/10 mg
28 Tablette(n)
29.02
47.00
20 %
Tabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Inegy 10/10 mg
98 Tablette(n)
101.29
123.05
20 %
Tabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Inegy 10/20 mg
28 Tablette(n)
32.70
50.85
20 %
Tabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Inegy 10/20 mg
98 Tablette(n)
114.16
136.60
20 %
Tabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Inegy 10/40 mg
28 Tablette(n)
38.10
56.55
20 %
Tabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Inegy 10/40 mg
98 Tablette(n)
131.50
154.90
20 %
Tabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Fosavance 70/2800
12 Tablette(n)
35.94
55.50
10 %
Wochentabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
L
IP
CI
Fosavance 70/5600
12 Tablette(n)
35.94
55.50
10 %
Wochentabletten: 2 Active Agents
Organon GmbH
B / SL / SO
FB
G
IP
CI
Cymbalta 30 mg
-
T
28 Kapsel(n)
14.94
32.40
10 %
gélules gastrorésistantes: Duloxetinum 30 mg
Eli Lilly (Suisse) SA
B / SL / SO
FB
G
IP
CI
Cymbalta 60 mg
-
T
14 Kapsel(n)
13.88
31.25
20 %
gélules gastrorésistantes: Duloxetinum 60 mg
Eli Lilly (Suisse) SA
B / SL / SO
FB
G
IP
CI
Cymbalta 60 mg
-
T
28 Kapsel(n)
26.30
44.55
20 %
gélules gastrorésistantes: Duloxetinum 60 mg
Eli Lilly (Suisse) SA
B / SL / SO
FB
G
IP
CI
Cymbalta 60 mg
-
T
84 Kapsel(n)
76.79
98.55
20 %
gélules gastrorésistantes: Duloxetinum 60 mg
Eli Lilly (Suisse) SA
B / SL / SO
FB
G
IP
CI
Multilind
24 ml
2.34
11.80
10 %
Nystatinum 100 UI
Dermapharm AG
B / SL / SG
FB
G
IP
CI
Bilol comp. 5/12.5
30 Tablette(n)
4.13
13.75
10 %
Filmtabletten: 2 Active Agents
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Bilol comp. 5/12.5
100 Tablette(n)
11.89
29.35
10 %
Filmtabletten: 2 Active Agents
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Bilol comp. 10/25
30 Tablette(n)
6.79
16.60
10 %
Filmtabletten: 2 Active Agents
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Bilol comp. 10/25
100 Tablette(n)
21.20
39.45
10 %
Filmtabletten: 2 Active Agents
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CI
Ventavis
30 Ampulle(n)
803.47
890.25
10 %
Inhalationslösung: Iloprostum 10 µg/ml
Bayer (Schweiz) AG
B / SL
FB
G
IP
Propofol MCT Fresenius 10
mg/ml
5 1 Ampulle(n) à 20 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 10
mg/ml
5 x 20 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 20
mg/ml
5 1 Ampulle(n) à 20 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 10
mg/ml
10 x 20 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 10
mg/ml
10 x 50 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 20
mg/ml
10 x 50 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 10
mg/ml
10 x 100 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Propofol MCT Fresenius 20
mg/ml
10 x 100 ml
PR
PR
k.A.
Fresenius Kabi
(Schweiz) AG
B
FB
G
SIP
IP
CI
Exjade 125 mg
28 Tablette(n)
390.38
464.55
k.A.
Dispersible Tabletten: Deferasiroxum 125 mg
Novartis Pharma
Schweiz AG
B
FB
G
SIP
IP
CI
Exjade 125 mg
84 Tablette(n)
995.47
1153.30
k.A.
Dispersible Tabletten: Deferasiroxum 125 mg
Novartis Pharma
Schweiz AG
B
FB
G
SIP
IP
CI
Exjade 250 mg
28 Tablette(n)
640.22
751.35
k.A.
Dispersible Tabletten: Deferasiroxum 250 mg
Novartis Pharma
Schweiz AG
B
FB
G
SIP
IP
CI
Exjade 250 mg
84 Tablette(n)
1632.58
1852.05
k.A.
Dispersible Tabletten: Deferasiroxum 250 mg
Novartis Pharma
Schweiz AG
B
FB
G
SIP
IP
CI
Exjade 500 mg
28 Tablette(n)
1049.97
1213.05
k.A.
Dispersible Tabletten: Deferasiroxum 500 mg
Novartis Pharma
Schweiz AG
B
FB
G
SIP
IP
CI
Exjade 500 mg
84 Tablette(n)
2677.42
2990.35
k.A.
Dispersible Tabletten: Deferasiroxum 500 mg
Novartis Pharma
Schweiz AG
B
FB
G
IP
CI
Inegy 10/80 mg
28 Tablette(n)
PR
PR
k.A.
Tabletten: 2 Active Agents
Organon GmbH
B
FB
G
IP
CI
Fosavance 70/2800
4 Tablette(n)
12.49
30.00
k.A.
Wochentabletten: 2 Active Agents
Organon GmbH
B
FB
G
IP
CI
Fosavance 70/5600
4 Tablette(n)
12.49
30.00
k.A.
Wochentabletten: 2 Active Agents
Organon GmbH
B
FB
G
IP
CI
Duraphat Fluorid 5 mg/g
Tube(n) à 51 g
PR
16.20
k.A.
Dentalpaste: Fluoridum 5 mg
Gaba Schweiz AG
B / LPPV
FB
G
IP
CI
Duraphat Fluorid 5 mg/g
3 x 51 g
PR
PR
k.A.
Dentalpaste: Fluoridum 5 mg
Gaba Schweiz AG
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home